John J. Orloff Sells 2,115 Shares of Alexion Pharmaceuticals (ALXN) Stock

Alexion Pharmaceuticals (NASDAQ:ALXN) EVP John J. Orloff sold 2,115 shares of the stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $118.53, for a total transaction of $250,690.95. Following the transaction, the executive vice president now owns 31,790 shares in the company, valued at $3,768,068.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

NASDAQ ALXN opened at $118.20 on Thursday. The firm has a market capitalization of $25.97 billion, a price-to-earnings ratio of 22.91, a P/E/G ratio of 1.05 and a beta of 1.11. Alexion Pharmaceuticals has a 12-month low of $102.10 and a 12-month high of $149.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.35 and a quick ratio of 2.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.18. The business had revenue of $930.90 million during the quarter, compared to analysts’ expectations of $920.50 million. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $1.38 earnings per share. equities analysts anticipate that Alexion Pharmaceuticals will post 6.28 earnings per share for the current year.

ALXN has been the topic of a number of recent research reports. Nomura increased their price objective on shares of Alexion Pharmaceuticals to $165.00 and gave the company a “buy” rating in a research note on Thursday, April 12th. BidaskClub downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, March 27th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 10th. ValuEngine downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Finally, Robert W. Baird set a $160.00 target price on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $158.37.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Delpha Capital Management LLC purchased a new position in shares of Alexion Pharmaceuticals in the fourth quarter worth $102,000. Point72 Asia Hong Kong Ltd raised its holdings in shares of Alexion Pharmaceuticals by 3,156.7% in the first quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 947 shares during the last quarter. CNB Bank purchased a new position in shares of Alexion Pharmaceuticals in the fourth quarter worth $150,000. Lucia Wealth Services LLC purchased a new position in shares of Alexion Pharmaceuticals in the first quarter worth $191,000. Finally, Financial Gravity Wealth Inc. purchased a new position in shares of Alexion Pharmaceuticals in the first quarter worth $211,000. 92.26% of the stock is owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit